Evidence map›Paper›PMID 24892497›Full record

ArticleBioconjugate chemistry2014

Optimization of SERS tag intensity, binding footprint, and emittance.

John P Nolan, Erika Duggan, Danilo Condello

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Multiplexed TEM Specimen Preparation and Analysis of Plasmonic Nanoparticles.Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

John P NolanLa Jolla Bioengineering Institute Suite 210 3535 General Atomics Court San Diego, California 92121, United States.
Erika Duggan
Danilo Condello

Funding

TRD #3: An automated and streamlined pipeline for in-situ molecular microscopyP41GM103310 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2012 to 2021
$14.7M
Raman Flow Cytometry for Diagnostics and Drug DiscoveryR01EB003824 · NIBIB · SCINTILLON INSTITUTE FOR PHOTOBIOLOGY · PI NOLAN, JOHN P · 2004 to 2014
$12.2M
NIBIB NIH HHS R01 EB003824NIGMS NIH HHS 9 P41GM103310NIGMS NIH HHS P41 GM103310
6 · The paper itself

Abstract

Nanoparticle surface enhanced Raman scattering (SERS) tags have attracted interest as labels for use in a variety of applications, including biomolecular assays. An obstacle to progress in this area is a lack of standardized approaches to compare the brightness of different SERS tags within and between laboratories. Here we present an approach based on binding of SERS tags to beads with known binding capacities that allows evaluation of the average intensity, the relative binding footprint of particles in a SERS tag preparation, and the size-normalized intensity or emittance. We tested this on four different SERS tag compositions and show that aggregated gold nanorods produce SERS tags that are 2-4 times brighter than relatively more monodisperse nanorods, but that the aggregated nanorods are also correspondingly larger, which may negate the intensity if steric hindrance limits the number of tags bound to a target. By contrast, SERS tags prepared from smaller gold nanorods coated with a silver shell produce SERS tags that are 2-3 times brighter, on a size-normalized basis, than the Au nanorod-based tags, resulting in labels with improved performance in SERS-based image and flow cytometry assays. SERS tags based on red-resonant Ag plates showed similarly bright signals and small footprint. This approach to evaluating SERS tag brightness is general, uses readily available reagents and instruments, and should be suitable for interlab comparisons of SERS tag brightness.

Indexed as

Fluorescent DyesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAvidinBreast NeoplasmsColoring AgentsErb-b2 Receptor Tyrosine KinasesFemaleFlow CytometryGoldHumansMetal NanoparticlesMicrospheresNanotubesSerum Albumin, BovineSilverAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAvidinColoring AgentsErb-b2 Receptor Tyrosine KinasesFluorescent DyesGoldneutravidinSerum Albumin, BovineSilverTrastuzumab

Identifiers

PMID24892497
PMCPMC4215889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.